Socioeconomic Disparities in the Presentation and Treatment of Graves’ Disease and Thyroid Eye Disease

REFERENCES

• Lee PP, West SK, Block SS, et al. Surveillance of disparities in vision and eye health in the United States: An expert panel’s opinions. Am J Ophthalmol 2012;154:S3–7.
   PubMed Web of Science ®Google Scholar
• Hudak DT, Magoon EH. Poverty predicts amblyopia treatment failure. J AAPOS 1997;1:214–5.
   PubMedGoogle Scholar
• Nessim M, Denniston AK, Nolan W, et al. Research into glaucoma and ethnicity (ReGAE) 8: Is there a relationship between social deprivation and acute primary angle closure? Br J Ophthalmol 2010;94:1304–6.
   PubMed Web of Science ®Google Scholar
• Ryskulova A, Turczyn K, Makuc DM, et al. Self-reported age-related eye diseases and visual impairment in the United States: Results of the 2002 national health interview survey. Am J Public Health 2008;98:454–61.
   PubMed Web of Science ®Google Scholar
• Sukumar S, Spencer F, Fenerty C, et al. The influence of socioeconomic and clinical factors upon the presenting visual field status of patients with glaucoma. Eye (Lond) 2009;23:1038–44.
   PubMed Web of Science ®Google Scholar
• Edmunds MR, Huntbach JA, Durrani OM. Are ethnicity, social grade, and social deprivation associated with severity of thyroid-associated ophthalmopathy? Ophthal Plast Reconstr Surg 2014;30:241–5.
   PubMed Web of Science ®Google Scholar
• Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010;362:726–38.
   PubMed Web of Science ®Google Scholar
• Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull 2011;99:39–51.
   PubMed Web of Science ®Google Scholar
• Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17:456–520.
   PubMed Web of Science ®Google Scholar
• Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 2012;26:273–9.
   PubMed Web of Science ®Google Scholar
• Brent GA. Clinical practice: Graves’ disease. N Engl J Med 2008;358:2594–605.
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223–43.
   PubMedGoogle Scholar
• Baskin HJ, Cobin RH, Duick DS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8:457–69.
   PubMedGoogle Scholar
• Costagliola S, Morgenthaler NG, Hoermann R, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease. J Clin Endocrinol Metab 1999;84:90–7.
   PubMed Web of Science ®Google Scholar
• Macchia E, Concetti R, Borgoni F, et al. Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: Their incidence, significance and clinical usefulness. Autoimmunity 1989;3:103–12.
   PubMed Web of Science ®Google Scholar
• Takasu N, Oshiro C, Akamine H, et al. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjects. J Endocrinol Invest 1997;20:452–61.
   PubMed Web of Science ®Google Scholar
• Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994;92:477–588.
   PubMedGoogle Scholar
• Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002;12:855–60.
   PubMed Web of Science ®Google Scholar
• Wiersinga WM, Smit T, van der Gaag R, et al. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J Endocrinol Invest 1988;11:615–9.
   PubMed Web of Science ®Google Scholar
• Khoo DH, Ho SC, Seah LL, et al. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 1999;9:1175–80.
   PubMed Web of Science ®Google Scholar
• Acuna OM, I Athannassaki, Paysse EA. Association between thyroid-stimulating immunoglobulin levels and ocular findings in pediatric patients with Graves disease. Trans Am Ophthalmol Soc 2007;105:146–50; discussion 50–1.
   PubMedGoogle Scholar
• Bartley GB, Gorman CA. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol 1995;119:792–5.
   PubMed Web of Science ®Google Scholar
• European Group on Graves, Wiersinga WM, Perros P, et al. Clinical assessment of patients with Graves’ orbitopathy: The European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006;155:387–9.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 2008;18:333–46.
   PubMed Web of Science ®Google Scholar
• Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013;98:1443–9.
   PubMed Web of Science ®Google Scholar
• Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid 2010;20:777–83.
   PubMed Web of Science ®Google Scholar
• Tellez M, Cooper J, Edmonds C. Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 1992;36:291–4.
   PubMed Web of Science ®Google Scholar
• Lim SL, Lim AK, Mumtaz M, et al. Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves’ disease. Thyroid 2008;18:1297–301.
   PubMed Web of Science ®Google Scholar
• Chng CL, Seah LL, Khoo DH. Ethnic differences in the clinical presentation of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab 2012;26:249–58.
   PubMed Web of Science ®Google Scholar
• Dechairo BM, Zabaneh D, Collins J, et al. Association of the TSHR gene with Graves’ disease: The first disease specific locus. Eur J Hum Genet 2005;13:1223–30.
   PubMed Web of Science ®Google Scholar
• Tomer Y. Mechanisms of autoimmune thyroid diseases: From genetics to epigenetics. Annu Rev Pathol 2014;9:147–56.
   PubMed Web of Science ®Google Scholar
• Vestergaard P. Smoking and thyroid disorders: A meta-analysis. Eur J Endocrinol 2002;146:153–61.
   PubMed Web of Science ®Google Scholar
• American Thyroid Association. The Clark T. Sawin History Resource Center: Thyroid History Timeline. Available at: http://www.thyroid.org/events/thyroid-history-timeline/Accessed May 16, 2015.
   Google Scholar
• Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid 1991;1:129–35.
   PubMedGoogle Scholar
• Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 2012;97:4549–58.
   Google Scholar
• Bartalena L, Burch HB, Burman KD, et al. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf) 2014;84:115–20.
   Google Scholar
• Elfenbein DM, Schneider DF, Havlena J, et al. Clinical and socioeconomic factors influence treatment decisions in Graves’ disease. Ann Surg Oncol 2015;22:1196–9.
   PubMed Web of Science ®Google Scholar
• Snyder S, Govednik C, Lairmore T, et al. Total thyroidectomy as primary definitive treatment for Graves’ hyperthyroidism. Am Surg 2013;79:1283–8.
   PubMed Web of Science ®Google Scholar
• Sundaresh V, Brito JP, Wang Z, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: A systematic review and network meta-analysis. J Clin Endocrinol Metab 2013;98:3671–7.
   PubMed Web of Science ®Google Scholar
• Lowery AJ, Kerin MJ. Graves’ ophthalmopathy: The case for thyroid surgery. Surgeon 2009;7:290–6.
   PubMed Web of Science ®Google Scholar
• Torring O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: Treatment with antithyroid drugs, surgery, or radioiodine: A prospective, randomized study: Thyroid Study Group. J Clin Endocrinol Metab 1996;81:2986–93.
   PubMed Web of Science ®Google Scholar
• Perros P, Zarkovic M, Azzolini C, et al. PREGO (presentation of Graves’ orbitopathy) study: Changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 2015;99:1531–5.
   PubMed Web of Science ®Google Scholar
• Verity DH, Rose GE. Acute thyroid eye disease (TED): Principles of medical and surgical management. Eye (Lond) 2013;27:308–19.
   PubMed Web of Science ®Google Scholar
• Dharmasena A. Selenium supplementation in thyroid associated ophthalmopathy: An update. Int J Ophthalmol 2014;7:365–75.
   PubMed Web of Science ®Google Scholar
• Hales IB, Thomas ID. Treatment of thyroid ophthalmopathy with corticoid analogues. Australas Ann Med 1962;11:113–7.
   PubMedGoogle Scholar
• Mainville NP, Jordan DR. Effect of orbital decompression on diplopia in thyroid-related orbitopathy. Ophthal Plast Reconstr Surg 2014;30:137–40.
   PubMed Web of Science ®Google Scholar
• Jin J, Sandoval V, Lawless ME, et al. Disparity in the management of Graves’ disease observed at an urban county hospital: A decade-long experience. Am J Surg 2012;204:199–202.
   PubMed Web of Science ®Google Scholar
• Stein JD, Childers D, Gupta S, et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 2015;133:290–6.
   PubMed Web of Science ®Google Scholar